Selective inhibition of BET bromodomains epigenetic signaling interferes with the bone-associated tumor vicious cycle
1INSERM UMR957, équipe labélisé Ligue 2012, Nantes, France; 2Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Université de Nantes, Nantes Atlantique Universités, EA3822, 1 Rue Gaston Veil, 44035 Nantes, France; 3Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston Massachusetts 02115, USA; 4Department of Medicine, Harvard Medical School, 25 Shattuck Street, Boston Massachusetts 02115, USA; 5Division of Oncology, Adhesion and Metastasis Laboratory, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
ba0003pp103